The Prodigy Project, a renowned organization with a 14-year legacy of empowering young storytellers, artists, and leaders, is thrilled to announce the launch of its newest initiative: Prodigy Innovator Camp. This transformative five-day program is designed to help teen entrepreneurs uncover their
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union RAHWAY, N.J. — (BUSINESS WIRE) — $MRK #MRK — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, on Tuesday
BETHESDA, Md. — (BUSINESS WIRE) — Curator Hotel & Resort Collection proudly announces that eight of its distinguished member properties have been recognized in the prestigious Forbes Travel Guide 2025 Star Award rankings, a globally respected benchmark for excellence in hospitality.
Straight Talk Wireless shows the power of unlimited data by putting extra money in people’s pockets during this taxing time. NEW YORK — (BUSINESS WIRE) — Straight Talk Wireless, a leading prepaid brand covered by Verizon’s 5G network and
MOORESTOWN, N.J. — (BUSINESS WIRE) — OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, is introducing significant enhancements to its Infinity® Automated Storage and Retrieval System (AS/RS). Enhanced features include a 15
SAN DIEGO — (BUSINESS WIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that the Alarum Technologies class action lawsuit seeks to represent purchasers or acquirers of Alarum Technologies Ltd. (NASDAQ: ALAR) securities between March 14, 2024 and
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, clinical response was maintained in nearly half of patients for Psoriasis Area and
— (PITCH PR) — Talent assessments aren’t new. Most companies already use them — in fact, 80% of Fortune 500 companies rely on them. Unfortunately, many of them do not have a clearly defined strategy in place for their use.
Results presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2025) Treatment with UGN-102 resulted in durable complete response (CR) rates across subgroups with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) CR rates were: 82.8% for patients